Naftifine hydrochloride 2% + Placebo + Naftin® 2% (Naftifine hydrochloride 2%)
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tinea Pedis
Conditions
Tinea Pedis
Trial Timeline
Mar 1, 2015 → Dec 1, 2015
NCT ID
NCT02633813About Naftifine hydrochloride 2% + Placebo + Naftin® 2% (Naftifine hydrochloride 2%)
Naftifine hydrochloride 2% + Placebo + Naftin® 2% (Naftifine hydrochloride 2%) is a phase 3 stage product being developed by GenZum Life Sciences for Tinea Pedis. The current trial status is completed. This product is registered under clinical trial identifier NCT02633813. Target conditions include Tinea Pedis.
What happened to similar drugs?
3 of 10 similar drugs in Tinea Pedis were approved
Approved (3) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02633813 | Phase 3 | Completed |
Competing Products
20 competing products in Tinea Pedis